Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare ...

Former Wisconsin Rep. Mike Gallagher joined 'America's Newsroom' to discuss Trump's tariff threat against China and his ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...